Abstract In sub-Saharan Africa, simple biomarkers of liver fibrosis are needed to scale-up
hepatitis B treatment. We conducted an individual participant data meta-analysis of 3,548 …

Despite the heavy disease burden posed by hepatitis B, around 90% of people living with
hepatitis B are not diagnosed globally. Many of the affected populations still have limited or …

Abstract Background & Aims Chronic hepatitis B virus (HBV) infection accounts for 30%‐
50% of cirrhosis related deaths in sub‐Saharan Africa (SSA). Since HBV‐related cirrhosis is …

Summary Background The World Health Organization seeks to eliminate viral hepatitis as a
public health threat by 2030. This review and meta-analysis aims to evaluate the …

Background: International guidelines for hepatitis B infection (HBV) recommend initiating
antiviral treatment based on viral replication with inflammation or fibrosis. HBV viral loads …

Background & Aims Strategies to implement HBV screening and treatment are critical to
achieve HBV elimination but have been inadequately evaluated in sub-Saharan Africa …

Background Current clinical guidelines recommend treating chronic hepatitis B virus (HBV)
infection in a minority of cases, but there are relatively scarce data on evolution or …

Background Hepatitis B is the leading cause of cirrhosis and liver cancer in sub-Saharan
Africa. To reduce mortality, antiviral treatment programs are needed. We estimated …

Background Clinical management of chronic hepatitis B virus (HBV) infection is complex and
access to antiviral treatment remains limited in sub-Saharan Africa. International guidelines …

Racial, ethnic, and socioeconomic disparities exist in the prevalence and natural history of
chronic liver disease, access to care, and clinical outcomes. Solutions to improve health …